Legend Biotech Appoints Alan Bash as President of CARVYKTI®
Legend Biotech (NASDAQ: LEGN) has appointed Alan Bash as President of CARVYKTI® in a newly created position. Bash will manage CARVYKTI's continued growth and oversee commercial, technical operations, and quality functions. The appointment follows CARVYKTI's recent FDA and European Commission approvals for label expansion. Bash brings extensive experience as former CEO of ZielBio and Checkmate Pharmaceuticals, plus a 23-year career at Bristol Myers Squibb where he led the U.S. launch of Opdivo® and expansion of other cancer treatments. CARVYKTI is currently the fastest launched CAR-T product on the market.
Legend Biotech (NASDAQ: LEGN) ha nominato Alan Bash come Presidente di CARVYKTI® in una posizione recentemente creata. Bash gestirà la continua crescita di CARVYKTI e supervisionerà le operazioni commerciali, tecniche e le funzioni di qualità. La nomina segue le recenti approvazioni della FDA e della Commissione europea per l'espansione dell'etichetta di CARVYKTI. Bash porta con sé una vasta esperienza come ex CEO di ZielBio e Checkmate Pharmaceuticals, oltre a una carriera di 23 anni in Bristol Myers Squibb, dove ha guidato il lancio di Opdivo® negli Stati Uniti e l'espansione di altri trattamenti per il cancro. Attualmente, CARVYKTI è il prodotto CAR-T lanciato più rapidamente sul mercato.
Legend Biotech (NASDAQ: LEGN) ha nombrado a Alan Bash como Presidente de CARVYKTI® en una nueva posición creada. Bash gestionará el continuo crecimiento de CARVYKTI y supervisará las operaciones comerciales, técnicas y de calidad. La designación sigue a las recientes aprobaciones de la FDA y de la Comisión Europea para la expansión de la etiqueta. Bash aporta una amplia experiencia como ex CEO de ZielBio y Checkmate Pharmaceuticals, además de una carrera de 23 años en Bristol Myers Squibb, donde lideró el lanzamiento de Opdivo® en EE.UU. y la expansión de otros tratamientos contra el cáncer. Actualmente, CARVYKTI es el producto CAR-T más rápidamente lanzado en el mercado.
레전드 바이오텍 (NASDAQ: LEGN)는 앨런 배시를 CARVYKTI®의 회장직에 새로 임명했습니다. 배시는 CARVYKTI의 지속적인 성장 관리를 책임지며 상업, 기술 운영 및 품질 기능을 감독합니다. 이번 임명은 CARVYKTI의 최근 FDA 및 유럽 위원회의 라벨 확장 승인을 따른 것입니다. 배시는 ZielBio와 Checkmate Pharmaceuticals의 전 CEO로서의 폭넓은 경험과 함께, 미국에서 Opdivo®의 출시 및 다른 암 치료제의 확장을 이끌었던 브리스톨 마이어스 스큅에서의 23년 경력을 가지고 있습니다. 현재 CARVYKTI는 시장에서 가장 빠르게 출시된 CAR-T 제품입니다.
Legend Biotech (NASDAQ: LEGN) a nommé Alan Bash au poste de Président de CARVYKTI® dans un nouveau poste créé. Bash gérera la croissance continue de CARVYKTI et supervisera les opérations commerciales, techniques et les fonctions qualité. Cette nomination fait suite aux récentes approbations de la FDA et de la Commission européenne pour l'expansion de l'étiquette de CARVYKTI. Bash apporte une vaste expérience en tant qu'ancien PDG de ZielBio et Checkmate Pharmaceuticals, ainsi qu'une carrière de 23 ans chez Bristol Myers Squibb, où il a dirigé le lancement d'Opdivo® aux États-Unis et l'expansion d'autres traitements contre le cancer. CARVYKTI est actuellement le produit CAR-T le plus rapidement lancé sur le marché.
Legend Biotech (NASDAQ: LEGN) hat Alan Bash zum Präsidenten von CARVYKTI® in einer neu geschaffenen Position ernannt. Bash wird das fortwährende Wachstum von CARVYKTI verwalten und die kommerziellen, technischen Abläufe sowie die Qualitätsfunktionen überwachen. Die Ernennung erfolgt nach den kürzlichen Genehmigungen von CARVYKTI durch die FDA und die Europäische Kommission zur Etiketterweiterung. Bash bringt umfangreiche Erfahrungen als ehemaliger CEO von ZielBio und Checkmate Pharmaceuticals mit, sowie eine 23-jährige Karriere bei Bristol Myers Squibb, wo er die US-Einführung von Opdivo® und die Erweiterung anderer Krebsbehandlungen leitete. CARVYKTI ist derzeit das am schnellsten eingeführte CAR-T-Produkt auf dem Markt.
- Recent FDA and European Commission approvals for CARVYKTI label expansion
- CARVYKTI achieves status as fastest launched CAR-T product in market
- Strategic hire brings extensive oncology commercialization experience
- None.
Newly created position to lead efforts focused on continued growth and sales
SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.
“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”
Mr. Bash served as Chief Executive Officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as President and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®. Mr. Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.
“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” said Mr. Bash. “I am excited about the opportunity to support the continued success of the CARVYKTI franchise and work with the Legend Biotech team and our collaboration partner, Johnson & Johnson, to fulfill CARVYKTI’s potential to transform the treatment paradigm for multiple myeloma.”
Mr. Bash earned his B.A. from Georgetown University and his M.B.A. from Columbia Business School.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 19, 2024. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
Who is the new President of CARVYKTI at Legend Biotech (LEGN)?
What recent regulatory approvals has CARVYKTI received for Legend Biotech (LEGN)?
What is Alan Bash's previous experience before joining Legend Biotech (LEGN)?
